Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s Pazdur Calls Accelerated Approval An “Interim Decision” With Ariad In Mind

This article was originally published in RPM Report

Executive Summary

Three days before Ariad ceded to FDA’s request to suspend marketing of its lung cancer drug Iclusig, the agency’s top cancer drug reviewer discussed how he views the accelerated approval process.

You may also be interested in...



An Artificial Intelligence Milestone For US FDA

A project to validate a depression severity measurement tool that employs artificial intelligence for use in drug trials is moving forward at FDA. The milestone is a sign of things to come – and of the incremental process for AI adoption by the regulator.

Advanced Manufacturing Technology Designation Guidance Uses Broad Criteria For ‘Novel’

In US FDA’s draft, mandated by in the current user fee legislation, contract manufacturers can also vie for a designation. CDER ETT and CBER CATT teams will play a key role in the process.

FDA Drug Development Meetings May Be Better Model For Future CMS Patient-Listening Sessions

The ability for Medicare officials to follow-up on patient testimony could make the sessions more informative. They also don’t all have to be the same.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS081072

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel